The Dual Nature of Microglia in Alzheimer's Disease: A Microglia-Neuron Crosstalk Perspective

Zhen Xie1,2, Jie Meng3, Zhou Wu4,5

  • 1Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science, Department of Biology, Beijing Institute of Technology, Beijing, China.

Insights

Microglia have dual roles in Alzheimer's disease (AD), impacting neuron health and amyloid pathology. Understanding these complex interactions is key for developing effective AD treatments targeting microglia.

Area of Science:

  • Neuroimmunology
  • Neuroscience
  • Pathology

Background:

  • Microglia are key immune cells in the brain, increasingly implicated in Alzheimer's disease (AD) pathogenesis.
  • The precise role of microglia in AD remains controversial, with evidence suggesting both beneficial and detrimental effects.
  • Microglia-neuron interactions are central to understanding AD pathology and potential therapeutic targets.

Purpose of the Study:

  • To review the dual and opposing roles of microglia in Alzheimer's disease.
  • To examine the impact of microglia-neuron interactions on AD pathogenesis.
  • To discuss current and future therapeutic strategies targeting microglia for AD treatment.

Main Methods:

  • Literature review of studies investigating microglia function in AD.
  • Analysis of neuroimmune crosstalk and its effects on neuronal health.
  • Evaluation of microglia's role in amyloid deposition and blood-brain barrier integrity.

Main Results:

  • Microglia exhibit opposing functions, including synaptic pruning (detrimental) and synapse formation (beneficial).
  • Neuroimmune interactions can lead to neuroinflammation, neuronal death, and altered amyloid-beta phagocytosis.
  • Microglia influence major AD pathologies like amyloid plaques and blood-brain barrier permeability.

Conclusions:

  • Microglia play a complex, dual role in Alzheimer's disease, necessitating a nuanced therapeutic approach.
  • Targeting microglia-neuron interactions offers potential for novel AD treatment strategies.
  • Further research is needed to define precise molecular targets for microglia-based AD therapies.